As a mage, I just want to pursue the truth

Chapter 145 2022 Annual Financial Report

Lithium metal material external patent authorization.

Graphene coatings only sell manufacturing equipment and do not license patents.

Firmly hold those with higher technical content in your hands, and authorize patents for those with relatively low technical content.

This method of operation was thought up by the executives of Kechuang Bio.

They believe that while maximizing the interests of the company, it can also ensure that the technology does not leak.

You can see my graphene coating structure, but you can't guess our specific implementation path.

Just like everyone knows what the underlying principle of the lithography machine is, but re-engraving requires a lot of manpower, material resources and time costs.

In the future, the graphene coating can continue to be optimized, and after the technology forms a certain barrier, it will have an absolute monopoly advantage.

If it can achieve the technical advantages of ASML, Kechuangbio will have a deeper moat.

Therefore, Kechuang Biotech bought a piece of land in Gusu and has already begun to recruit people as a production base for graphene coating equipment.

In 2022, the profit of endorphin alone will be more than 100 billion yuan. There is too much cash lying on the books of Kechuang Bio, and too much money and not knowing how to spend it is also a trouble.

Just like Mihayou had too much money lying on its books, and then invested in a company whose main business is controllable nuclear fusion, and it was still the lead investor in the A round.

There are too many liquid funds on the books, so that the higher authorities hope that Kechuangbio will issue private placements, but Kechuangbio can't find a reason for the private placement for a while.

Gao Minghuan has been working in the industry for many years, and he quickly understood the plan of Kechuangbiology. He secretly said in his heart that this separation method can guarantee the lower limit of Kechuangbio for the next 20 years.

New energy is a major trend, and monopolizing one of the indispensable segments can at least provide a steady stream of cash flow.

Gao Minghuan thought about endorphins, brain-computer connections, and graphene-coated equipment, only to realize that the other party actually monopolizes a lot of fields.

He was shocked in his heart, but he didn't show his expression on the surface: "LG Chem is willing to pay a high price to lock in your company's graphene coating equipment in advance."

Cheng Gang: "Sorry, we have already signed supply agreements with Ningde Times, BYD and other companies. Even if we want to supply manufacturers such as LG Chem, we have to wait for our production capacity to be surplus."

"If there is any news in the future, I will notify your company as soon as possible."

"The annual revenue of Kechuang Biology is close to 2500 billion RMB, of which the brain-computer connection revenue accounts for more than the biomedical business.

Its annual non-net profit is about 1500 billion RMB, with an average daily profit of 4.1 million RMB. The growth rate of net profit exceeds [-]%, far exceeding expectations, ranking fifth among listed companies.

This is also the first time in the past ten years that a non-financial company has entered the top ten net profit list of listed companies in Huaguo. "

After Kechuang Bio's 2022 full-year financial report is expected to come out, Kechuang Biology, which has been breaking through the market value of RMB 2 trillion since the opening of the second day, directly raised the daily limit again.

You must know that the market value of the Ningde era, whose net profit is only one-tenth of Kechuang Bio, is 1.1 trillion RMB.

The technical content of Kechuangbiology is higher than that of Ningde era.

And recently, there have been repeated news that Kechuangbio has entered the lithium battery industry, which has further contributed to the further rise of Kechuangbio.

"It's amazing. It's the first time I've seen such an awesome technology company with a net profit of 1500 billion. Monopoly is really too profitable."

A net profit of 1500 billion sounds exaggerated, but given a set of data, it is not the most exaggerated.

The net profit of Huaguo Tobacco in 2021 is close to 1.3 trillion yuan, and the net profit of Huaguo Investment in 2020 is close to 7000 billion yuan.

"In fact, it's okay. Goose Factory's annual net profit this year is 1964 billion RMB, and its market value is only 4 trillion HKD. The market value of Kechuang Biology is about [-] trillion to [-] trillion. Those who shouted that the unit price exceeded [-] yuan Just shout."

The total share capital of Kechuang Biology is 4 million shares, and the unit price exceeds [-], which means that the market value exceeds [-] trillion.

One million in one hand, which only institutions can afford.

The target prices of Soochow, CICC, and China Securities Investment are all between 8000 yuan and 1 yuan.

Among them, the title of Soochow is: "Don't be afraid of floating clouds to cover your eyes, just because you are at the highest level."

Slightly exaggerated.

"Upstairs, the logic of Kechuang Bio is completely different from Goose Factory. This is not the same type of company. Social traffic has byte to compete with Goose Factory. In terms of cloud services, there are Ali, Huawei, Qiandu and Goose Factory. compete.

Not to mention the game field, the competitors have gone to sea.

And does Kechuangbio have competitors in the field of endorphins and brain-computer connection?Musk's Neuralink can only be used in the mid-range mobile phone market, and the recognition rate is far inferior to Kechuangbio.

The moat of Kechuangbio is much deeper than that of Goose Factory.Not to mention that Kechuangbiology still has two favorable production capacities of brain-computer connection VR and new lithium battery materials that have not been released.

In my opinion, a market value of [-] trillion yuan is not the ceiling of science and technology innovation at all, but just a starting point. "

"It's almost done. Kechuang Biology is indeed very good, but does it have anything to do with our retail investors? Can you afford to buy one?

I worked so hard to spend 50 yuan of working capital to play on the science and technology innovation board, which is only enough to buy a first-hand science and innovation creature.

This company does not make money for retail investors, only institutional trading, just watching it go up, the daily transaction volume is ridiculously small. "

"When will Kechuang Biotech split up? If we don't split up, retail investors will not be able to enjoy the benefits of corporate development. We also want to grow together with great companies!"

Split means that 1 stock is divided into 10. When the stock price is too high to be conducive to trading, this kind of treatment is done.

About 30 years ago, there was a ticket called Yuyuan Mall, whose market value rose from 800 yuan to 10500 yuan.

(As for whether Yuyuan Mall has been split, I really don’t remember)
"I took a look and found that Kechuangbiology's R&D investment in the first three quarters reached 600 billion RMB, and I estimate that most of it was spent on brain-computer connection chips.

Whether it is the R&D center in England, or the massive poaching of people in the field of AI chips this year, the president of the Cambrian who dug out publicly shouted, saying that it is possible not to poach the R&D teams of domestic friends, but to poach foreign R&D teams .

There is no way to be poached, domestic AI companies have been poached all over.

Judging from this matter, even with such a high revenue and such a deep moat, Kechuang Bio still invests a lot of money in research and development.

It can be seen from the enterprising heart of the company's management.Zheng Li is only in his 20s now, and his strong aggressiveness can last at least 20 years.

Coupled with its top research talents, I am very optimistic about the future development of Kechuangbiology.

There's only one problem, it's too expensive.This is not a problem of Kechuangbiology, but my problem. "

After the 2022 annual report of Kechuang Bio was announced, it attracted heated discussions in the capital market.

The net profit of 1500 billion is very high, but there are still higher companies ahead.

However, there are only two giants in the country that have achieved such a high net profit, Goose Factory and Ari.

Only the goose factory has maintained a growth trend, and it has been in a growth trend. Although the growth rate has slowed down, it is still rising.

阿狸2019年全年净利润在1633亿rmb，2020年全年净利润在1512亿rmb，等到了2021年全年净利润只有711亿rmb。

It is precisely because of the negative growth that Ahri's market value fell from 5 trillion HKD to below 1 trillion HKD.

As a rising star, Kechuang Biotech has achieved a net profit of over 1500 billion RMB in just four years.

The net profit growth has remained above 100% year after year, and the secondary market is infinitely optimistic.

Retail investors can't buy it if they want to buy it, and they dare not buy it. It's too expensive, and it costs 50 yuan per hand.

Domestic institutions and investment institutions in Europe and the United States have been increasing positions and rushing to raise funds.

Technology creates wealth, but the creation of wealth in this way still has a big impact on the entrepreneurs in Huaguo.

The impact on the industry is comparable to that of Alipay helping Tianhong to sell Yu’e Bao on behalf of Alipay. It directly changed from an unknown small fund company to the largest fund company. The scale of Yu’e Bao alone exceeded one trillion yuan.

Affected by this, Huaguo's angel investors prefer R&D companies rather than Internet companies.

In the past two years, the life of Internet companies has become more and more difficult. Ari will inevitably have a sharp drop in net profit, let alone start-ups.

It is becoming more and more difficult to get a large number of users by relying on subsidies, expand the scale and then go public to collect money.

"How can I see the 2022 annual financial report of Kechuang Bio?"

Since the company is rich and does not need to squeeze bottom-level employees to make profits, Kechuangbio basically does not work overtime, and the performance appraisal does not depend on your working hours.

In addition, Kechuang Biology’s recruitment over the years is very friendly to graduates of biology, materials science, and chemistry, and the four major tiankeng majors account for three.

Sci-Tech Biology not only recruits a lot, but also gives a lot. Of course, the requirements are also high.

Therefore, on Zhihu, there has always been a high degree of discussion on issues related to science and technology innovation.

"Thank you for your invitation, as a doctor of biology who was recruited by the school this year, let's talk about why Kechuangbio can obtain such a high profit.

First of all, the R&D team of Kechuangbio is very large. The R&D team of the Suzhou R&D Center has more than 3000 people, more than one-third of whom are Ph.D.

There are about 1000 people in Jiangcheng, about 1000 people in Lion City, and about 800 people in the R&D center in England.

The proportion of doctorates in Lion City and England is 50.00%, and the proportion of PhDs in Jiangcheng is similar to that of Gusu.

Kechuangbio spends almost 300 billion on labor costs every year.

The treatment for R&D personnel is comparable to that of programmers in big factories. Their working hours are much longer than ours. We basically don’t have to work overtime, let alone big and small weeks.

The scientific research atmosphere is very good. No matter which direction you have ideas, you can find people in the corresponding direction in the internal system to discuss with you.Certainly limited to the biological aspects of what I do.

At present, Kechuang Bio's profit source is mainly Zheng Dong's research and development results, endorphins and brain-computer connection.

Among them, the brain-computer connection is mainly followed by the R&D team in the Lion City, because Mr. Zheng himself is also in the Lion City. Whether it is a brain-computer connection to a mobile phone or a brain-computer connection to VR, all R&D tasks are placed in the Lion City.

The research and development centers in Gusu and Jiangcheng are mainly engaged in the optimization of the industrial production process of endorphins, and the cost has been reduced by 20.00% so far.

In addition, it is mainly engaged in the research and development of innovative drugs. At present, there are [-] innovative drug pipelines in the combined two domestic R&D centers.

It is a shame that innovative drugs have not yet created profits.

The R&D center in England is mainly for AI chips and AI algorithms. It is said that this R&D center will be allocated to Kechuang Semiconductor in the future.Kechuang Semiconductor is a subsidiary established only last year, mainly making brain-computer connection chips.

Our investment in scientific research is absolutely very high, and the investment in R&D is second only to Huawei. "

(End of this chapter)